NeedleBay supports Insulin Safety Week 2025 with real-life success story
Retired paramedic Paul Thompson credits an innovative device with transforming his diabetes management.
As Insulin Safety Week 2025 gets underway this week, NeedleBay is proud to support the campaign by sharing the story of Paul Thompson – a retired paramedic living with diabetes – who describes the device as “revolutionary” in helping him take control of his condition.
Paul said: “NeedleBay has been revolutionary in my blood sugar control. I now have the confidence to take medication and injections away from home.”
During his working life, Paul needed a diabetes management system that offered flexibility and reliability. “As a paramedic, I couldn’t always rely on getting back to base for meals or medication,” he explained. “NeedleBay gave me the freedom and peace of mind to carry my insulin securely and use it safely wherever I was.”
Designed to simplify the handling and storage of insulin pen needles, NeedleBay offers a compact, user-friendly solution that promotes safer injection practices. The device allows users to organise and store their insulin pen needles in a way that ensures they are used only once, provides clear proof of use and reduces the risk of accidental needlestick injuries.
Peter Brenikov, Director of NeedleBay, said: “We are delighted to sponsor Insulin Safety Week 2025, an important event that brings healthcare professionals together to strengthen their knowledge of insulin therapy, improve patient outcomes and minimise risks.
“At NeedleBay, we are committed to providing solutions that support safe and effective diabetes management. The latest version of NeedleBay was developed directly in response to real-life user feedback, ensuring it meets the everyday needs of people living with diabetes.”
Insulin Safety Week will be held May 12 to 18, for further information please visit www.insulinsafetyweek.com
For more information about NeedleBay visit www.needlebay.com
Insulin Safety Week 2025 has been funded by embecta, D&H Food and Nutrition Limited, NeedleBay and Sanofi who have had no input into any arrangements or content.